Abstract
AbstractWe aimed to summarize the cancer risk among patients with indication of group I pharmaceuticals as stated in monographs presented by the International Agency for Research on Cancer working groups. Following the PRISMA guidelines, a comprehensive literature search was conducted using the PubMed database. Pharmaceuticals with few studies on cancer risk were identified in systematic reviews; those with two or more studies were subjected to meta-analysis. For the meta-analysis, a random-effects model was used to calculate the summary relative risks (SRRs) and 95% confidence intervals (95% CIs). Heterogeneity across studies was presented using the Higgins I square value from Cochran’s Q test. Among the 12 group I pharmaceuticals selected, three involved a single study [etoposide, thiotepa, and mustargen + oncovin + procarbazine + prednisone (MOPP)], seven had two or more studies [busulfan, cyclosporine, azathioprine, cyclophosphamide, methoxsalen + ultraviolet (UV) radiation therapy, melphalan, and chlorambucil], and two did not have any studies [etoposide + bleomycin + cisplatin and treosulfan]. Cyclosporine and azathioprine reported increased skin cancer risk (SRR = 1.32, 95% CI 1.07–1.62; SRR = 1.56, 95% CI 1.25–1.93) compared to non-use. Cyclophosphamide increased bladder and hematologic cancer risk (SRR = 2.87, 95% CI 1.32–6.23; SRR = 2.43, 95% CI 1.65–3.58). Busulfan increased hematologic cancer risk (SRR = 6.71, 95% CI 2.49–18.08); melphalan was associated with hematologic cancer (SRR = 4.43, 95% CI 1.30–15.15). In the systematic review, methoxsalen + UV and MOPP were associated with an increased risk of skin and lung cancer, respectively. Our results can enhance persistent surveillance of group I pharmaceutical use, establish novel clinical strategies for patients with indications, and provide evidence for re-categorizing current group I pharmaceuticals into other groups.
Funder
Korean Foundation for Cancer Research
National Evidence-based Healthcare Collaborating Agency
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. IARC Monogr Eval Carcinog Risk Chem Man. IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: Some aziridines, N-, S- & O-mustards and selenium 1–268 (1975).
2. IARC Monogr Eval Carcinog Risk Chem Hum. Some pharmaceutical drugs 1–337 (1980).
3. IARC Monogr Eval Carcinog Risk Chem Hum. Some antineoplastic and immunosuppressive agents 1–411 (1981).
4. IARC Monogr Eval Carcinog Risks Hum. Pharmaceuticals. Volume 100 A. A review of human carcinogens 1–401 (2012).
5. Some Drugs and Herbal Products. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 1–419 (2016).